ability bacteria activate terminal complement component serum patient cystic fibrosis terminal complement component c3 c9 contribute host defense infection study performed determine defective activation c3 c9 bacteria contributes pathogenesis recurrent pulmonary infection cystic fibrosis bacteria incubated serum patient cystic fibrosis 30 minute consumption available c3 serum control patient two patient chronic severe bronchiectasis based result present study unlikely defective activation c3 c9 contributes pathogenesis increased susceptibility pulmonary infection patient